Novel CCR1 antagonists with improved metabolic stability.
The synthesis, biological activity, and pharmacokinetic profile of novel CCR1 antagonists are described.
Brown
Matthew F
MF
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. matthew_f_brown@groton.pfizer.com
Avery
Mike
M
Brissette
William H
WH
Chang
J H
JH
Colizza
Kevin
K
Conklyn
Maryrose
M
DiRico
Amy P
AP
Gladue
Ronald P
RP
Kath
John C
JC
Krueger
Suzanne S
SS
Lira
Paul D
PD
Lillie
Brett M
BM
Lundquist
Greg D
GD
Mairs
Erin N
EN
McElroy
Eric B
EB
McGlynn
Molly A
MA
Paradis
Timothy J
TJ
Poss
Christopher S
CS
Rossulek
Michelle I
MI
Shepard
Richard M
RM
Sims
Jeff
J
Strelevitz
Timothy J
TJ
Truesdell
Susan
S
Tylaska
Laurie A
LA
Yoon
Kwansik
K
Zheng
Deye
D
D000818:Animals; D004285:Dogs; D000882:Haplorhini; D010599:Pharmacokinetics; D054389:Receptors, CCR1; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*
D054389:Receptors, CCR1; D019707:Receptors, Chemokine